Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Gliatech (GLIA) -- Ignore unavailable to you. Want to Upgrade?

To: PHILLIP FLOTOW who wrote (1175)	1/12/2000 4:25:00 PM
From: PHILLIP FLOTOW	Respond to of 2001

Company Press Release SOURCE: Gliatech Inc. Gliatech Announces Resignation of John A. Redmond CLEVELAND, Jan. 12 /PRNewswire/ -- Gliatech Inc. (Nasdaq: GLIA - news) today announced that the Board of Directors has accepted the resignation of John A. Redmond, President and Chief Operating Officer effective January 12, 2000. Mr. Redmond joined the Company in February 1999 as Vice President, General Manager Medical Devices, and has served as President and Chief Operating Officer since October 1999. Thomas O. Oesterling, Ph.D., Chairman and Chief Executive Officer will resume the additional responsibilities of President. The Company has commenced a search for a new President to replace Mr. Redmond. In commenting on Mr. Redmond's departure, Dr. Oesterling stated ``John's leadership and contribution to Gliatech have been significant and we wish him well in his new endeavors.' ``My goal of becoming the Chief Executive Officer of Gliatech cannot be realized in a time frame acceptable to me for my personal growth objectives,' said Mr. Redmond. ``I wish my friends and colleagues every success in fulfilling what I believe is a significant business opportunity at Gliatech.' Gliatech was formed in 1988 to discover, develop and commercialize therapeutic products based on understanding the properties of glial cells, a major component of the nervous system. The Company applies its core glial research to developing innovative products for major unmet human health care needs. SOURCE: Gliatech Inc. PHIL